Athos Borradori-Gianella
Suresnes, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Journal: The Lancet. Haematology
Published: March 06, 2022
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.
Journal: Lancet (London, England)
Published: May 07, 2020
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
Journal: The Lancet. Neurology
Published: January 02, 2020
Neuromyelitis optica spectrum disorder: Patient experience and quality of life.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: January 11, 2019
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 21, 2014
A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course.
Journal: Leukemia & lymphoma
Published: November 22, 2013
Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile.
Journal: Leukemia research
Published: October 25, 2013
A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors.
Journal: Targeted oncology
Published: April 09, 2013
A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors.
Journal: Investigational new drugs
Published: December 21, 2012
A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies.
Journal: Leukemia research
Published: December 19, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026